Midatech files CTA for MTD201 ’s carcinoid cancer and acromegaly trial

UK-based specialist pharmaceutical firm Midatech Pharma has submitted a clinical trial application (CTA) for its drug candidate MTD201 to treat carcinoid cancer and acromegaly.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

In conclusion, acromegaly registries offer a global view of the disease with no “a priori” assumptions. This is of outmost importance, because of the large amount of data and the huge number of associated comorbidities. This will help to establish guidelines for management of this rare disease.
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
CONCLUSIONS: Coexistence of acromegaly and numerous other tumors suggests a common etiology of these disorders. However, no genetic abnormality could be identified with the tests that have been performed. PMID: 30742299 [PubMed - as supplied by publisher]
Source: Endokrynologia Polska - Category: Endocrinology Authors: Tags: Endokrynol Pol Source Type: research
Authors: Hancerliogullari O, Senocak R, Kaymak S, Lapsekili E, Sinan H Abstract Acromegaly is a chronic endocrine disease, typically caused by a pituitary adenoma leading to increased circulating GH levels and increased IGF-I secretion by peripheral tissues. Gastrointestinal diseases related acromegaly such as colon cancers, adenomatous polyps, and dolichocolon are much less known. We aimed to present a case of complete colonic volvulus in a patient with acromegaly. A 60-year-old male patient presented with the complaints of inability to pass gas or stool, worsening distension, and pain for one week. The clinical e...
Source: Annali Italiani di Chirurgia - Category: Surgery Tags: Ann Ital Chir Source Type: research
ConclusionOctreotide SC depot provided higher exposure (AUC) than octreotide IM, maintained biochemical control in patients with acromegaly and symptom control in patients with functioning NETs, and was well tolerated with a safety profile consistent with octreotide IM.ClinicalTrials.gov identifierNCT02299089.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Authors: Boguszewski CL, Boguszewski MCDS Abstract Several components of the GH axis are involved in tumor progression and GH-induced intracellular signaling has been strongly associated with breast cancer susceptibility in genome-wide association studies. In the general population, high IGF-I levels and low IGFBP-3 levels within the normal range are associated with the development of common malignancies, and components of the GH-IGF signaling system exhibit correlations with clinical, histopathological and therapeutic parameters in cancer patients. Despite promising findings in preclinical studies, anti-cancer the...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
Abstract Carney complex is a rare, autosomal dominant, multiple endocrine neoplasia and lentiginosis syndrome, caused in most patients by defects in the PRKAR1A gene, which encodes the regulatory subunit type 1α of protein kinase A. Inactivating defects of PRKAR1A lead to aberrant cyclic-AMP-protein kinase A signaling. Patients may develop multiple skin abnormalities and a variety of endocrine and non-endocrine tumors. Endocrine manifestations include primary pigmented nodular adrenocortical disease, that may cause Cushing syndrome, growth-hormone secreting pituitary adenoma or pituitary somatotropic hyperpl...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: Exp Clin Endocrinol Diabetes Source Type: research
Exp Clin Endocrinol Diabetes DOI: 10.1055/a-0753-4943Carney complex is a rare, autosomal dominant, multiple endocrine neoplasia and lentiginosis syndrome, caused in most patients by defects in the PRKAR1A gene, which encodes the regulatory subunit type 1α of protein kinase A. Inactivating defects of PRKAR1A lead to aberrant cyclic-AMP-protein kinase A signaling. Patients may develop multiple skin abnormalities and a variety of endocrine and non-endocrine tumors. Endocrine manifestations include primary pigmented nodular adrenocortical disease, that may cause Cushing syndrome, growth-hormone secreting pituitary adenom...
Source: Experimental and Clinical Endocrinology and Diabetes - Category: Endocrinology Authors: Tags: Review Source Type: research
AbstractPurposeTo investigate the nodular thyroid disease (NTD) and the natural course of thyroid nodules in patients with acromegaly.Methods138 patients with acromegaly (73  F/65 M), whose initial thyroid ultrasonography performed in our university hospital, were included in this study. The frequencies of NTD, papillary thyroid cancer (PTC) and associated factors on nodule formation were investigated at initial assessment. Patients who had NTD continued to follow-up (n = 56) were re-evaluated with a ultrasonography performed after a mean 7-years follow-up period. The nodule size changes were compar...
Source: Pituitary - Category: Endocrinology Source Type: research
Abstract Suppressor of cytokine signaling (SOCS) 2, a negative regulator of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), which is associated with acromegaly and cancers, is a promising candidate molecule for treating various diseases. To facilitate its use in protein therapy, we designed and constructed a human SOCS2 protein containing a membrane-permeable peptide sequence and expressed it in an Escherichia coli system. The partially purified recombinant protein was effectively delivered into several cancer cell lines and inhibited cell growth. Biochemical analysis showed that the recombinant SOCS...
Source: Bioscience, Biotechnology, and Biochemistry - Category: Biochemistry Authors: Tags: Biosci Biotechnol Biochem Source Type: research
Authors: Yuen KC, Popovic V Abstract Previous studies have implicated the growth hormone (GH)/IGF-I axis as an important mediator of cancer risk in humans and animals. Evidence supporting this notion is derived from animal studies, epidemiological observations, patients with acromegaly and from therapeutic manipulation of GH and IGF-I actions. Therefore, the use of GH therapy in patients with a history of malignancy raises hypothetical safety concerns. Reassuringly, GH therapy in childhood cancer survivors has not been confirmed to increase the cancer risk. Conversely, the risk of occurrence of a second neoplasm ma...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
More News: Acromegaly | Cancer | Cancer & Oncology | Clinical Trials | Pharmaceuticals